Balancing the Scales: Patient Load vs. Care Quality in Diabetes

Q: It’s hard to keep up with all the research and know which treatments, targets and tech truly help.

Consensus papers distil hundreds of studies into clear, practical guidance on staging, insulin, targets, CGM, pumps, etc., so clinics and families aren’t guessing.

Q: People with diabetes care feel reduced to A1c, while mental health, school, money and burnout get ignored.

The guidelines tie numbers to quality of life , mental health and Time in Range, making care more human, not just mathematical .

Q: How can we argue for better access and support? It’s tough to push for CGM, pumps, psychology or fair access when it sounds like “just my opinion.”

Consensus papers call out equity and psychosocial care as essential, giving HCPs and advocates a strong evidence-based “backbone” to demand better systems, not just more effort from families.

Balancing the Scales: Patient Load vs. Care Quality in Diabetes

ISPAD is the International Society for Pediatric and Adolescent Diabetes, the society has released consensus for linical Practice Consensus Guidelines 2024 – Type 1 Diabetes Focus (Ch. 2 Screening & Staging, Ch. 8 Glycemic Targets, Ch. 9 Insulin & Adjunctive Treatments, Ch. 16 & 17 Diabetes Technologies)

Published Date:

Dec 11, 2024

Published By:

Michael J Haller, Martin de Bock, Eda Cengiz, Torben Biester, Martin Tauschmann and colleagues, on behalf of the International Society for Pediatric and Adolescent Diabetes (ISPAD)

Approved By:

To be

Decoded By:

Asra H. Ahmed (MBA, PGCE in Assessment Learning disability) & Devanagana Thakuria from The Diabesties Foundation.

10 mins to read

Word Wizard

CGM

AID

TIR

Stage 1 Type 1 Diabetes

Stage 2 Type 1 Diabetes

Vital Nuggets

ISPAD 2024 explains that Type 1 diabetes often begins years before symptoms, and that finding two or more islet autoantibodies means early Type 1, where good screening plus education can reduce DKA at diagnosis and, in some settings, allow immune therapy like teplizumab to delay the move to full clinical diabetes.
Care is centered on basal–bolus insulin (by injections or pump), and premixed insulin is no longer preferred for children. CGM, insulin pumps and automated insulin delivery (AID) are treated as essential tools that reliably improve time in range and reduce severe lows and DKA, not as optional “nice extras.”
Glycemic targets are firmer but still humane: an A1c around 5–7.0% is encouraged for many children and teens, but only if this can be achieved safely, without increasing severe hypoglycemia or harming mental health.
Across all of this runs a clear message on equity: gaps in access to insulin, glucose strips, CGM, pumps and new drugs are framed as a matter of fairness and justice rather than individual effort, and closing these gaps is described as a core part of good Type 1 care.

Summary Snap
Shots

ISPAD 2024 reframes Type 1 diabetes in kids and teens as a staged, life-long condition that can be detected earlier, treated more precisely and supported more fairly. It pulls together evidence for staging with autoantibodies, realistic HbA1c/TIR goals, modern insulin options, and diabetes tech (CGM, pumps, AID), while repeatedly stressing that emotional health and access matter as much as numbers

Prime Insight

ISPAD is the main global expert group for diabetes care in children and teenagers. Their guidelines are evidence-based “how to” instructions that show doctors what good care should look like—how Type 1 (and other diabetes types in young people) should be diagnosed, treated, and supported.

T1D is framed as a staged condition:
Screening, staging & preserving beta-cell function is an integral part of the consensus paper.
Stage 1: 2 or more islet autoantibodies, normal glucose.

Stage 2: 2 or more autoantibodies + blood sugars that are starting to look off, even if they’re not in the full diabetes range yet.

Stage 3: Clinical Type 1 diabetes means the blood tests are now clearly in the diabetes range.
Sometimes there are no obvious symptoms yet (Stage 3a), and sometimes there are the classic signs (Stage 3b) like a lot of thirst, peeing all the time, losing weight, and feeling very tired.

Stage 4: Long-standing T1D.
Having two or more autoantibodies is not “borderline” – it is early (pre-symptomatic) Type 1, with very high lifetime risk of progressing to Stage 3.

Screening can be family-based or general population. When it includes education and structured follow-up, it:

Reduces DKA at diagnosis.
Allows families to prepare emotionally and practically.
Creates space to discuss immune therapies like teplizumab in Stage 2 where available.

Glycemic targets & glucose monitoring –

Those living with type 1 diabetes and use a CGM or an AID system it is recommended:
It’s okay to aim a bit lower – an HbA1c around 6.5% or less, if you can do it safely and it doesn’t make life too stressful.
However, for children and teens not on an AID system it is recommended: A good, realistic goal is anHbA1c around 7.0% or less, with room to adjust based on age, support, and mental health.

We don’t look at HbA1c alone anymore:

We also look at Time in Range (TIR) – the percent of time your glucose is between 70–180 mg/dL (3.9–10 mmol/L).
When you’re using CGM, HbA1c + TIR together tell a more complete story, rather than using data point on its own.

Targets are recommended to be personalized based on hypoglycemia risk, mental health, access to tech, and family capacity.

ISPAD consensus pointers agree better early management leads to long-term outcomes. Earlier, safer tightening of glucose (A1c closer to 6.5–7%)lower rates of eye and kidney disease decades later, in line with DCCT-style data, On monitoring: CGM is treated as standard of care where available, improving A1c, TIR, severe hypoglycemia and DKA rates.

ISPAD says clearly that these guidelines are meant to lighten the load, improve quality of life, and be free for everyone to read around the world, in many languages (ispad.org).

So, this isn’t just “another medical document” – it’s a global playbook for young people with diabetes, designed to be clear, visual, science-based and inclusive, so more families, HCPs and advocates can use it in real life.

it’s a global playbook for young people with diabetes, designed to be clear, visual, science-based and inclusive, so more families, HCPs and advocates can use it in real life.

Insulin & adjunctive therapies

Basal–bolus therapy (MDI or pump) is the standard of care for youth with T1D.

Premixed insulin twice daily is not preferred for children. The consensus paper recommends the use of faster-acting mealtime analogues. Ultra-long basal insulins and how to dose them.

ISPAD gives clear guidance on “extra” diabetes medicines (like pramlintide, metformin, GLP-1 medicines and SGLT tablets):

They are sometimes added to insulin in older teens, usually when there is extra weight, or very high insulin doses, and only when the benefits and risks are carefully discussed.
Massive emphasis: these medicines are add-ons to insulin, never replacements.
The chapter also has a strong access and affordability section. It explicitly calls for health systems and governments to ensure insulin is available without financial hardship, especially in low- and middle-income settings.

Diabetes technologies – insulin delivery & glucose monitoring –

Pump and AID chapter summarizes advances since 2022. There is lots of practical “how-to” within the consensus statement:

Infusion-set management and lipo-hypertrophy.
Dealing with alarm fatigue, sensor errors, skin reactions.
Choosing tech based on age, developmental stage, and family preference.
Strong equity language – the chapter and editorial both highlight disparities in tech access and call for closing these gaps.

“ISPAD’s Clinical Practice Consensus Guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide!”

Why does care look so different from clinic to clinic? We are always struggling to know: How do we know what ‘good care’ is?”

Families and HCPs often follow different rules for the same child (screening, targets, pumps, etc.) ISPAD solution: A shared global playbook so everyone works from the same map for children and teens with diabetes.

It’s hard to keep up with all the research and know which treatments, targets and tech truly help.

Consensus papers distil hundreds of studies into clear, practical guidance on staging, insulin, targets, CGM, pumps, etc., so clinics and families aren’t guessing.

People with diabetes care feel reduced to A1c, while mental health, school, money and burnout get ignored.

The guidelines tie numbers to quality of life, mental health and Time in Range, making care more human, not just mathematical.

How can we argue for better access and support? It’s tough to push for CGM, pumps, psychology or fair access when it sounds like “just my opinion.”

Consensus papers call out equity and psychosocial care as essential, giving HCPs and advocates a strong evidence-based “backbone” to demand better systems, not just more effort from families.